Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 12/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28297314 | 0.69 | AVPR1A (0.38) | — | |
| SCHEMBL11418621 | 0.68 | NISCH (0.55) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL1862935 | 0.68 | AVPR1A (0.46) | — | |
| SCHEMBL6054462 | 0.67 | NISCH (0.69) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11839444 | 0.65 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9828967 | 0.65 | AVPR1A (0.40) | — | |
| SCHEMBL9619232 | 0.65 | NISCH (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL28833094 | 0.64 | BRD4 (0.41) | — | |
| SCHEMBL19157283 | 0.63 | AVPR1A (0.40) | — | |
| SCHEMBL305967 | 0.63 | BRPF1 (0.47) | NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0620732-B1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-5418234-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1995-05-23 | — | — | US | disclosed |
| EP-0549594-B1 | (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES AND METHODS FOR USING SAME | ALLERGAN INC (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5373010-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1994-12-13 | — | — | US | disclosed |
| EP-0620732-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN, INC. (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5326763-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0422878-B1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN INC (US) | 1994-04-27 | — | — | EP | disclosed |
| EP-0422878-B1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN INC (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5300504-A | Increasing renal fluid flow | ALLERGAN, INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5300504-A | Increasing renal fluid flow | ALLERGAN, INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5231096-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1993-07-27 | — | — | US | disclosed |
| WO-1993013771-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN, INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5204347-A | Reduction in intraocular pressure; increase renal flow; alteration in the rate of fluid transport in the gastrointestinal tract | ALLERGAN, INC. (US) | 1993-04-20 | — | — | US | disclosed |
| US-5204347-A | Reduction in intraocular pressure; increase renal flow; alteration in the rate of fluid transport in the gastrointestinal tract | ALLERGAN, INC. (US) | 1993-04-20 | — | — | US | disclosed |
| WO-1992013855-A1 | (2-IMIDAZOLIN-2-YLAMINO) TETRAHYDROQUINOLAXINES AND METHODS FOR USING SAME | ALLERGAN, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5077292-A | Gastrointestinal disordes; kidney and vision defects | ALLERGAN, INC. (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0422878-A1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN, INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0422878-A1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN, INC. (US) | 1991-04-17 | — | — | EP | disclosed |